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Available online 06 March 2019In the cyclic guanosine monophosphate (cGMP) signaling pathway, phosphodiesterase 6 (PDE6) maintains a
critical balance of the intracellular concentration of cGMP by catalyzing it to 5′ guanosine monophosphate (5′-
GMP). To gain insight into the mechanistic impacts of the PDE6 somatic mutations that are implicated in cancer
and retinitis pigmentosa, we ﬁrst deﬁned the structure and organization of the human PDE6 heterodimer using
computational comparative modelling. Each subunit of PDE6αβ possesses three domains connected through
long α-helices. The heterodimer model indicates that the two chains are likely related by a pseudo two-fold
axis. The N-terminal region of each subunit is comprised of two allosteric cGMP-binding domains (Gaf-A &
Gaf-B), oriented in the same way and interacting with the catalytic domain present at the C-terminal in a way
that would allow the allosteric cGMP-binding domains to inﬂuence catalytic activity. Subsequently, we applied
an integrated knowledge-driven in silicomutation analysis approach to understand the structural and functional
implications of experimentally identiﬁed mutations that cause various cancers and retinitis pigmentosa, as well
as computational saturation mutagenesis of the dimer interface and cGMP-binding residues of both Gaf-A, and
the catalytic domains. We studied the impact of mutations on the stability of PDE6αβ structure, subunit-
interfaces and Gaf-cGMP interactions. Further,we discussed the changes in interatomic interactions ofmutations
that are destabilizing in Gaf-A (R93L, V141M, F162 L), catalytic domain (D600N, F742 L, F776 L) and at the dimer
interface (F426A, F248G, F424N). This study establishes a possible link of change in PDE6αβ structural stability to
the experimentally observed disease phenotypes.
Crown Copyright © 2019 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural
Biotechnology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords:
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In living organisms, synchronized cellular communication among
integrated signaling circuits is necessary to ensure proper cellular func-
tion. Accurate signal transduction of extracellular cues to interior of the
cells is coordinated between multiple compartmentalized intracellular
signaling pathways through the recruitment of a distinct subset of sens-
ingmolecules [51,59]. So far 3000 signaling proteins and approximately
15 distinct second messenger molecules are known in mammals
[24,35]. In the late 1980s, nitric oxide (NO) was discovered as the ﬁrst
diffusible primary signaling molecule that binds and activates soluble
guanylate cyclase (sGC) to produce 3′, 5′cyclic guanosine monopho-
sphate (cGMP) from guanosine triphosphate (GTP). Cyclic guanosine
monophosphate is a vital secondary messenger molecule that elicitsiddiqi), tlb20@cam.ac.uk
r B.V. on behalf of Research Network
.speciﬁc biological effects by activating various effector proteins
through cGMP speciﬁc protein kinase (PKG). While cyclic nucleotide
phosphodiesterases (PDEs) hydrolyze cyclic GMP to 5′-GMP [9,27].
Phosphodiesterases act at the crossroad of multitude of intertwined
compartmentalized intracellular signaling pathways where they are
negative regulators of the concentration of cGMP and operate to
dampen its downstream signaling circuitry in speciﬁc subcellular com-
partments [20]. In the cGMP signaling pathway, homeostatic regulation
of signals propagating within the various interlinked intracellular com-
partments rely heavily on the dynamic organization of sGC, PKG
and PDE, multimeric signaling complexes as well as it depending on
the critical balance of primary and secondary diffusible messenger
molecules [1].
The phosphodiesterase superfamily is encoded by 21 genes that are
categorized into 11 structurally homologous isozyme subfamilies based
on their substrate speciﬁcity [1,20]. PDE6, known as photoreceptor
phosphodiesterase, is the only member of the enzymes superfamily
that predominantly expresses in the cytosol of retinal photoreceptorof Computational and Structural Biotechnology. This is an open access article under the CC
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tubules of kidneys and pineal gland [26]. Recently, a study reported sub-
cellular localization of retina-restricted PDE6 in the perinuclear region
of endothelial cells and suggested its signiﬁcant role in compartmental-
ized cGMP signaling pathways of endothelium [8]. In pineal glands,
PDE6 regulates light inducedmelatonin production. Throughmelatonin
production PDE6 indirectly regulates melanin production, sleep-wake
cycles, biological rhythms and cell repair mechanisms in response to
stress and disease [41,56,62]. PDE6, like the other ﬁve closely related
cGMP speciﬁc PDEs possess tandemly arranged GAF domains at the
N-terminal that controls dimer formation and act as allosteric binding
site of cGMP molecules [20]. Furthermore, the rod photoreceptor spe-
ciﬁc PDE6 is unique among its enzyme family members as it is com-
prised of two different catalytic subunits, an α subunit encoded by
PDE6A gene and a β subunit encoded by PDE6B. Both these subunits
helps in lowering the cGMP concentration by hydrolyzing it into
GTP [8,15].
Recent advances of in-depth DNA and RNA sequencing analyses of
cancer genomes are resulting into a growing repertoire of somatic mu-
tations in signaling proteins [13]. Abnormalities in the cGMP signaling
pathway have recently identiﬁed to amplify proliferative signaling in
human cancer [5]. Elevation of cGMP concentration, as a result of defects
and/or aberrant expression of photoreceptor speciﬁc PDE6, leads to
hyper-activation of PKG isoforms, which in turn contributes to the pro-
gression of malignant melanoma in skin and breast cancer cells [7,39]
and various kinds of cancer pathologies in lungs, stomach, endome-
trium and as well as in familial retinitis pigmentosa [14,16,23,32,55].
The Cancer Genome Atlas (TCGA) project has given insight into recur-
rent mutant genes in colorectal cancer (CRC) through large-scale
genome sequencing. They investigated somatic mutations and chromo-
somal trasnlsocations in various members of WNT, RAS-MAPK, PI3K,
TGF-β, P53 and DNA mismatch repair pathways that are responsible
for initiation and progression of CRC. In colorectal cancer samples
PDE6A and PDE6B genes were found to be hyper-mutated genes and
all the mutations are enlisted in OASIS, a multi-omic data repository
for cancer [22,42]. Expression of PDE6 isozymes has also been shown
in breast cancer cell lines [18]. In the presence of somatic missense
mutations, the negative regulatory effect of PDE6 on downstream
subcellular signaling pathways is compromised, which could serve as
an important means of acquisition of tumorigenesis in multiple experi-
mental models of human cancer [14,30]. The role of cGMP/PKG signal-
ing during excessive stimulation of mitogen-activated protein kinase/
extracellular signal-regulated kinase (MAPK/ERK) signaling pathway
has been established as central to molecular pathogenesis of approxi-
mately 40% of human melanomas. Cross talk of components of the
cGMP signaling pathway and Ca2+ signaling attenuatesMAPK/ERK pro-
liferative signaling inmelanoma cells [51]. PDE6 is crime partner of mu-
tated p53, through which it subvert cGMP signaling pathway. PDE6
isoforms are non-canonical co-receptors and effector molecule of
Wnt/Ca2+/NFAT signaling pathway as well [31,36]. Although experi-
mental evidence on expression of PDE6 mutations in cancer cell lines
is available [3,34] how these genomic alterations dictate normal cells
to acquire a diseased phenotype is still obscure.
Among all PDEs, very little structural information about multi-
domain organization of PDE6 is available as the active form of human
PDE6 is challenging to express in prokaryotic or eukaryotic expression
systems [45]. To gain insight into the structural implications of PDE6
mutations in cancer and retinitis pigmentosa, a computational approach
was adopted. Initially three-dimensional (3D) comparative models of
multi-domain human PDE6were built based on the solved crystal struc-
tures of closely related PDEs. In addition to experimentally known mu-
tations, saturation mutagenesis was also performed for the residues
located at the dimeric interface of the A and B chains, as well as the
cGMP-binding residues of Gaf-A and the catalytic domain to study
their role in the stability of the quaternary structure of the protein.
The current study is focused on the use of structure-driven methodsto explore the possible molecular mechanism and structural effects of
disease-causing mutations in PDE6. Following this, a comprehensive
knowledge-based in silico mutation analysis was carried out to predict
the effects and decipher the structural basis of destabilizing mutations
effecting PDE6 stability and function in normal cells.
2. Materials & Methods
2.1. Homology Modelling of PDE6
To understand themolecular architecture of human PDE6, compara-
tive modelling was performed using Modeller v 9.20 [50]. Like all other
cGMP speciﬁc PDEs, both PDE6α and β chains have tandem cGMP-
binding regulatory domains known as Gaf-A & Gaf-B in the N-terminal
region while the catalytic domain is located at C-terminus. Amino acid
sequences of PDE6α (UniProt ID: P16499) and PDE6β chains (UniProt
ID: P35913) were retrieved from UniProt. Sequences of both the chains
were aligned using Clustal W [58] and CLC workbench [63]. To select
closely related templates for both the chains, PSI-BLAST was performed
against all the known structures in the protein Databank (PDB).
Modsuite (Unpublished Skwark MJ, Ochoa-Montaño B and Blundell
TL), a comparative protein modelling pipeline comprised of programs
such as Baton, Fugue, Joy [40] and Modeller 9.17 [50], was used to
model the PDE6. Baton is used to perform structural alignment of
closely related homologs of query proteins followed by Fugue [53], a
distant homolog identiﬁcation tool that identiﬁes sequence-structure
correlations of query proteins with known/solved homologous. Se-
quence to structure alignment of Fugue is annotated/represented in
Joy which gives a graphical representation of local three dimensional
(3D) structural features of the protein sequence in structure alignment,
which makes analysis of conserved residues more tractable [40]. Based
on the Fugue alignment, Modeller uses a comparative/homology
modelling approach and builds structures of target proteins by identify-
ing the conserved structural features of closely related proteins [10]. To
model Gaf-A domain in α and β chains, the crystal structures of Gaf-A
domain of PDE6C in complex with cGMP (PDB ID: 3DBA [38]) and of
the Gaf-A domain of PDE5 (PDB ID: 2K31) were used as templates,
while for the Gaf-B domain, the solved structures of the Gaf-B domain
of PDE5 (PDB ID: 3LFV [61]& 3MF0 [61]) were used. For the Gaf-B do-
main of PDE6β, an additional template comprised of the crystal struc-
ture comprised of PDE2 Gaf-B region (PDB ID: 3IBJ) was also used.
While for C-terminal catalytic domain, the crystal structure of cGMP
bound to PDE5 catalytic domain (PDB ID: 1T9S [64]) and chimeric
PDE5/PDE6 catalytic domain (PDB ID: 3JWR [4]) were used as tem-
plates. Later, the crystal structure of PDE2 (PDB ID:3IBJ [43]) was used
as a template to borrow the structure of the central long α-helices, on
which all the individually modelled domains were assembled to
makeup a cGMP bound heterodimeric complex of PDE6αβ using UCSF
Chimera [46]. Root means square deviations (RMSD), DOPE score [52]
and GA341 values [21] of individual domain models and ﬁnal heterodi-
meric PDE6 model were calculated. Energy minimization of initial
models was performed using MMF94s force ﬁeld in UCSF Chimera and
quality assessments of initial and reﬁned PDE6αβmodels in complex
with cGMP were performed using RAMPAGE and Molprobity [11].
Pymol [17] was used for model analysis and ﬁgure illustrations.
2.2. Data Collection of PDE6 Mutations
Various experimental studies have reported missense mutations of
PDE6 and their implications in cancer [8,18,60] and retinitis pigmentosa
[12,19,33,37,49]. To explore the inﬂuence of thesemutations on the sta-
bility of the PDE6 structure, 145 missense mutations in the PDE6A gene
and 114mutations in the PDE6B gene were retrieved from catalogue of
somatic mutations in cancer (COSMIC) [25]. It is the world's largest
expert-curated cancer- speciﬁc catalogue of somatic mutations.We fur-
ther noticed that all the PDE6 mutations reported in the literature for
Fig. 1. Homology model of cGMP-bound PDE6 heterodimer showing PDE6α and PDE6β
chains. Each chain is comprised of Gaf-A, Gaf-B and catalytic domains connected
through α-helices.
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PDE6A and PDE6B respectively, are present in COSMIC as well. In addi-
tion to this, computational saturation mutagenesis was performed for
interfacial residues in order to understand how mutations affect the
structural stability of the PDE6αβ heterodimeric interface. Interface res-
idues of the PDE6αβ complex were identiﬁed using Pymol. Likewise,
saturation mutagenesis was also performed for cGMP-binding domains
(both Gaf-A & catalytic domains) of the PDE6 heterodimer in order to
understand the impact of mutations on the Gaf-A-cGMP (protein-
nucleic acid) interactions. The cGMP binding residues in Gaf-A and cat-
alytic domains were identiﬁed using Intermezzo (Ochoa-Montaño B,
Blundell TL – unpublished), an in house developed program for identi-
fying interatomic interactions.
2.3. In Silico Mutation Analysis of PDE6
To study the impacts of mutations on the stability of the PDE6αβ
dimer, the change in free energy of themodel was estimated using pro-
grams namely mutation cut off scanning matrix (mCSM) [47] and Site
Directed Mutator (SDM) [42]. Mutation cut off scanning matrix
(mCSM) has several modules; protein stability (mCSM), protein-
protein interaction (mCSM-PPI) and Protein-DNA (mCSM-NA).
Mutation cut off scanning matrix employs machine learning and
graph-based signatures which deﬁnes the wild-type residue environ-
ment based on a pairwise interatomic distance matrix. The distance
matrix of wild- type residues is then represented as a feature vector
and changes induced by mutations are represented as pharmacophore
count vector for mutant and wild type residues. Eight atomic pharm-
acophore features (positive, negative, hydrophobic, positive, hydrogen
acceptor and donor, sulphur, aromatic and neutral) are deﬁned in the
mCSM algorithm. An estimate of the difference between wild-type fea-
ture vector and mutant pharmacophore vector is included in the signa-
ture which also includes experimental parameters i.e. pH, solvent
accessibility and temperature. Final generated signature vector is than
employed to train the predictive classiﬁcation and regression model,
which calculates the change induced by mutations in terms of Gibbs
free energy (ΔΔG) of folding. Alongside this, we also used SDM [44] to
predict thermodynamic changes in PDE6 wild type and mutant struc-
tures by calculating a stability score. It calculates protein stability
score by estimating the probability of amino acid substitutions using
environment-dependent amino acid substitution tables derived from
homologous protein families. Mutant models were generated using
Andante [54], a tool integrated with SDM [44]. For mutant models,
Andante [54] applies a comparative modelling approach that uses
χ angle conservation probabilities to select lowest energy sidechain
conformations from homolog templates to ensure minimum root
mean square deviation (RMSD). To improve the overall accuracy of pre-
diction of mutations under consideration, we also used DUET [48] that
integrates both mCSM and SDM. Furthermore, mCSM-PPI was used to
determine the impact of mutations on the stability of the dimeric inter-
face and mCSM-NA for Gaf-A – cGMP interaction.
2.4. Selection/Filtering of PDE6 Mutations in Relation to Cancer
Frequency distributions ofmissensemutations in COSMIC for PDE6A
and PDE6B, according to their ΔΔG values, were analyzed through his-
tograms built using R-scripts. The effects of mutations predicted by
mCSMandSDMweremappedonto the PDE6αβ complex by developing
attribute ﬁles in UCSF Chimera using their ΔΔG values. Predicted effects
of saturation mutagenesis on the dimeric interface and cGMP-binding
regions of Gaf-A and catalytic domains were also mapped onto the
PDE6αβ complex. Later, those mutations within PDE6αβ that are re-
ported as cancer causingmutations in COSMICwere selected and stabil-
ity changes were predicted. Of these mutations, we focused on residues
that are important in cGMP- binding, and/or catalytic activity of
PDE6αβ as well as those involved in stabilization of the PDE6αβheterodimer. Additionally, those mutations that are common in cancer
and retinitis pigmentosa were also selected and analyzed.
Later, wemapped the interatomic interactions of wild type and mu-
tant residues of a few selected mutations in the cGMP-binding pocket
and dimeric interface, using Intermezzo in order to consider the struc-
tural effects in detail.
3. Results
3.1. Homology Model of PDE6
Sequence alignment of PDE6A and PDE6B revealed 71.4% sequence
identity. Sequence alignment is presented in Supplementary Fig. 1. For
comparative modelling, we ﬁrst built models of individual domains of
PDE6αβ chains encoded by PDE6A and PDE6B genes. Fugue generated
sequence-to-structure alignments of individual domains of PDE6α
and PDE6β chains with respect to their template structures; their pre-
dicted models are given in Supplementary Figs. 2 and 3 respectively.
Root- mean-square deviations (RMSD) of all individual models were
0.2–0.6 Åwith their respective templateswhile, Ramachandran analysis
revealed 96–98% residues in favorable regions. Individual domainswere
thenmodelled in a heterodimeric structure of cGMP bound PDE6with a
dyad symmetry as shown in Fig. 1. In our predicted model, chain A
(PDE6α) of PDE6 encoded by PDE6A gene includes residues from posi-
tions 53–823 while chain B (PDE6β) encoded by PDE6B gene is com-
prised of 68–831 amino acids. On each chain, tandem Gaf-A and Gaf-B
domains are organized oriented in same direction. Catalytic domains
of the two chains are rotated around the dyad axis with respect to the
tandem Gaf-A & B domains (see Fig. 1). The overall molecular architec-
ture of PDE6αβ heterodimer shows a parallel arrangement of both the
chains mediated through two long juxtaposed α-helices that makeup
the dimeric interface of the model. Both Gaf-A and catalytic domains
in PDE6αβ have cGMP molecules bound to them and additionally two
metal ions, a Mg2+ and a Zn2+ are also present in the catalytic pocket
of each promoter (see Fig. 1).
The domain organization of the predicted model is consistent with
the crystal structure of PDE2; however, our predicted model is in an
381A. Maryam et al. / Computational and Structural Biotechnology Journal 17 (2019) 378–389open conformation, whereas cGMP is bound to the catalytic pocket. Un-
like the crystal structure of the apo form of PDE2, the catalytic domains
swing away from the dimeric interface and are not contributing to the
dimer formation; rather they have anopen conformation of the catalytic
pocket. Quality analysis of PDE6αβ revealed 97.1% residues in the favor-
able regions and only 2.9% of the residues in the outlier region.
3.2. PDE6 Mutations Analysis
For chainα of the PDE6αβheterodimer, stability changes due to 145
mutations from multiple cancers were analyzed using mCSM-PS, SDM
and DUET. mCSM predicted 7.5% mutations (11/145) has stabilizing ef-
fect on PDE6 (ΔΔG N 0). While 97.5% mutations (131/145) were
destabilizing (ΔΔG b 0 kcal/mol). Of the destabilizing mutations,
89% (117/132) have a mild effect on the stability of PDE6α (ΔΔG N
−2.0 kcal/mol), while 12% of them are highly destabilizing mutations
(ΔΔG b −2.00 kcal/mol) (Fig. 2). mCSM predicted stability changes
were mapped onto the structure and are shown in Fig. 3a. Stability
changes (ΔΔG) predicted using mCSM -PS and SDM showed that the
majority of themappedmissensemutations aremildly affecting the sta-
bility and few positions having high destabilizing effects. Using SDM,
60% of the mutations (87/145) were predicted to confer mild changes
in stability while approximately 5% (7/145) were shown to be highly
destabilizing (Fig. 2). SDM predicted energy changes were mapped
onto the PDE6α chain and are shown in Fig. 3b. DUET predicted 78.6%
(114/145) as mildly destabilizing mutations while approximately
6% (9/145) are predicted as highly destabilizing (ΔΔG b 0 kcal/mol)
(Fig. 2).
To predict the impact of mutations on the protein- protein inter-
faces,mCSM-PPIprogramwasused.mCSM-PPI revealsonly3.7%(5)mu-
tations as highly destabilizing of interdomain, interchain or multimeric
signaling partner interactions. 89.6% of mutations (130/145) in the α-
chain were predicted to have mild effects on the protein- protein inter-
faces as their ΔΔG values range from −0.044 to −1.804 kcal/mol.Fig. 2. Frequency distribution graphs illustrating the distribution of experimentally known PDE6
NA, mCSM-PPI and SDM. The graph bars shows stabilizing mutations (ΔΔG ≥ 0 kcal/mol), sligh
(ΔΔG b−2.00 kcal/mol).To understand the impact of these missense mutations on binding of
cGMP at Gaf-A domain,mCSM-NAwas applied. 45% (65/145)were pre-
dicted to destabilize cGMP binding, while 4 mutations in the binding
pocket were shown as highly destabilizing which may disrupt cGMP
binding with Gaf-A domain (Fig. 2).
For the β chain of the PDE6αβ heterodimer, 114 missense muta-
tions reported from multiple cancers were analyzed in the current
study. mCSM predicted approximately 9% of the mutations (10/114)
to be stabilizing PDE6, while 91% of mutations (104/114) were pre-
dicted to be destabilizing. Out of these 114 destabilizing mutations,
approximately 94% (98/104) are mildly destabilizing (ΔΔG N −2.0
kcal/mol) while around 6% (6/104) were predicted as highly
destabilizing (ΔΔG b −2.00 kcal/mol) (Fig. 2). Stability changes pre-
dicted for 145 mutations were mapped onto the structure (Fig. 3c).
Using SDM, 64% (73/114) of the mutations were found to affect pro-
tein stability and approximately 8% were predicted to highly destabi-
lize PDE6β (9/114). DUET revealed 75% mutations as slightly
destabilizing and approximately 10% as highly destabilizing (Fig. 2).
SDM predicted stability changes were mapped on the PDE6β structure
as shown in Fig. 3d. Stability changes due to mutations in PDE6β at
the subunit interface with PDE6α (predicted using mCSM-PPI) indi-
cated that 6.1% (7) are stabilizing mutations, whereas 5% (6/114) are
highly destabilizing which may impact the heterodimer formation.
The remaining 88% of the mutations in PDE6β chain were predicted
to have mild destabilizing effects on protein- protein interfaces as
their ΔΔG values lie in range of −0.4 to −1.9 kcal/mol. Mutations
that affect the cGMP binding were predicted using mCSM-NA and
the results show 35% of the mutations (40/114) to be slightly
destabilizing cGMP binding whereas only one mutation was found to
be highly destabilizing and probably disrupt cGMP binding in the cat-
alytic pocket/Gaf-A domain (Fig. 2). Furthermore, mutation analysis of
17 retinitis-pigmentosa-speciﬁc missense mutations in PDE6A showed
that 9 mutations were also present in COSMIC databases, out of which
8 were found to be slightly destabilizing in terms of their ΔΔG valuesA and PDE6Bmutations based on ΔΔG values predicted throughDUET, mCSM-PS, mCSM-
tly damaging mutations (0 N ΔΔG ≥ −2.00 kcal/mol) and highly destabilizing mutations
Fig. 3. Heat maps based on mCSM and SDM predicted change in ΔΔG values of PDE6α and β chain. a) Shows mCSM while b) represents SDM predicted changes in protein stability of
PDE6α chain upon COSMIC mutations. Similarly, c) shows mCSM while d) represents SDM predicted changes in protein stability of PDE6 β chain upon COSMIC mutations. Effect of
mCSM and SDM predicted ΔΔG values for mutations occurring in PDE6αβ is depicted through a colored gradient scale, starting from blue indicating the average stabilizing effect (N0
kcal/mol) to highly destabilizing (b−2.00 kcal/mol) shown in red.
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tions were found common among cancer and retinitis pigmentosa.
Mutation analysis through aforementioned tools revealed that three
of them were slightly destabilizing (see Supplementary table 1),
while the missense mutation of the highly conserved catalytic residue
(D600N) reported, in both PDE6α and PDE6β chains, is signiﬁcantly
destabilizing the binding of metal ions in the cGMP-binding pocket
of the catalytic domain.
3.2.1. Experimentally Known PDE6 Mutations for Cancer
3.2.1.1. PDE6α Gaf-A Domain Missense Mutations; F162L, V141M, R93L.
Impact of mutations on the cGMP binding was predicted using mCSM-
NA and the stability changes were mapped on the Gaf-A domain
(Fig. 4a and b). In the Gaf-A domain of PDE6α, Lys-76, Ile-78, Leu-88,
Asn-80, Gln-90, Arg-93, Phe-113, Asn-114, Val-141, Cys-163 and Phe-
162 interact with cGMP (Fig. 4c). Backbone atoms of Ile-78, Asn-114,
Val-141 and sidechain atomsof Leu-88, Ile-140, Phe-162 formhydrogen
bond and van-der-Waals interactions with the cGMP molecule as
shown in Fig. 4c. Ring atoms of Phe-113 form π-π stacking interaction
with the purine ring of cGMP. Mutations in the residues that interact
with cGMP resulted in the loss of native binding interactions which
might affect the cGMP binding to Gaf-A domain.
Three mutations in the Gaf-A domain that are earlier reported in
COSMIC and are known to highly destabilize cGMP-Gaf-A interactions
are discussed below:
R93L: In wild type PDE6A, sidechain atoms of Arg-93 interacts with
the cGMP molecule by making a non-bonded edge-to-tilted (ET) inter-
action. Arg-93 also forms hydrogen bonds with His-116 and an ionic in-
teraction with Asp-92. Proximal hydrophobic interactions were also
observed with Leu-65, Cys-77 and Lys-76. These interactions of Arg-93
with the neighboring residues contribute to the shape and folding of
the cGMP-binding pocket in Gaf-A. For R93L mutation, mCSM-PS, SDM
and DUET predicted ΔΔG values as−1.211 kcal/mol,−1.01 kcal/mol
and−1.297 kcal/mol respectively, which shows that this mutation is
mildly destabilizing. However, predictions by mCSM-NA revealed that
this mutation is highly destabilizing to cGMP binding (ΔΔG =
−2.22 kcal/mol) (See Table 1). Further, analysis of interatomicinteractions using Intermezzo revealed loss of vital interactions with
cGMPmolecule as well as loss of native interactions with the surround-
ing residue environment i.e. Asp-92, His-116, Leu-76, Cys-77 (Fig. 5b).
V141 M: Valine at position 141 binds to the cGMP molecule and
neighboring backbone and sidechain atoms of Val-144 and Ala-145 re-
spectively through van der Waals interactions. Sulphur group of Met-
193 interacts with Val-141 through weak van der Waals interaction.
Within its surrounding residue environment, Val-141 also forms a
carbon-π interaction with the ring atoms of Phe-97 and Phe-113
(Fig. 5c). In the mutant form, Val-141 is substituted with a methionine,
which induces loss of bindingwith the cGMPmolecule in addition to the
change in the binding pattern with the surrounding residues. Mutation
analysis using mCSM, SDM and DUET and mCSM-PPI predicted it as a
mildly destabilizing mutation in terms of protein stability whereas
mCSM-NA indicated that mutation would highly destabilize cGMP
binding (ΔΔG =−4.978 kcal/mol). V141M brings about a change in
the binding pocket resulting in the loss of its carbon-π interaction
with Phe-113 and van der Waals interaction with the Met-193 as wild
type, while it retains van der Waals interactions with the backbone
atoms of Val-144 as well as with side chain atoms of Ala-145. The mu-
tant also forms methionine-π interaction with ring atoms of Phe-97
and hydrophobic interaction with Leu-108. Interaction of the mutant
residue with the surrounding residue environment other than the na-
tive ones in the wildtype, might affect the binding pocket conformation
and impact the cGMP binding (Fig. 5d).
F162L: F162L, another missensemutationwithin the binding pocket
of the Gaf-A domain, was predicted to have a mild destabilizing effect
(predicted by mCSM, DUET and SDM to be −1.381 kcal/mol, −1.95
kcal/mol,−1.492 kcal/mol respectively). This mutation mildly destabi-
lizes subunit interface and the cGMPbinding (see Table 1). Inwild-type,
F162 ring forms three weak hydrogen bonds (van der Waals) with the
cGMP molecule. The side chain oxygen atom of Thr-156 forms a
donor-π interaction with the ring atoms of F612 and it also shares a
dense network of proximal hydrophobic interactionswith the sidechain
atoms of Leu-89, Asp-159, His-161 and Asp-164 (Fig. 5e). Intermezzo
analysis revealed change in the cGMP binding pocket which resulted
in the loss of weak hydrogen bonds with cGMP as well as hydrophobic
interactions with His-161 and Asp-164. Additionally, the mutant
Fig. 4. a) Heat map showing the average predicted changes upon mutation in cGMP-binding residues of PDE6α Gaf-A domain using mCSM-NA (b). zoom in view of cGMP bound Gaf-A
domain and predicted effect of mutations in cGMP interacting residues of Gaf-A domain is shown through a colored gradient scale that starts from blue indicating the average stabilizing
effect (N0 kcal/mol), slightly destabilizing (≥−2.00 kcal/mol) (white) and highly destabilizing (b−2.00 kcal/mol) (highlighted in red). c) depicts Intermezzo analysis of cGMPbindingwith
thewild type residues of Gaf-A domain of PDE6 through non-covalent interactions. Red dotted lines indicate hydrogen bonds aswell as van derwal interactions of the cGMPmoleculewith
Leu-88, Asn-114, Val-141, Phe-162 and Cys-163. Hydrophobic interactions involving ring-ring and ring-atom interactions between cGMPmolecule and Phe-162, Ile-78, Gln-90 are shown
in grey color while inter-residue interactions of Ile-78, Asn-87 and Arg-93 with the ring atoms of the cGMP molecule are shown in light yellow color.
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hydrophobic interaction with Thr-156 (Fig. 5f).
3.2.2. PDE6A Catalytic Domain
In addition to the non-catalytic residues, the effect of missense
mutations on catalytic residues were also analyzed in the current
study. In PDE6α and PDE6β, catalytic residues within the active site
are conserved. Within the catalytic pocket, two metal ions (Mg2+,
Zn2+) and Tyr-558, His-559, His563, Asp-600, Thr-669, Leu-671, Glu-
741, Phe-742, Met-760, Gln-773 and Phe-776 were observed to have a
dense network of interactions with the cGMPmolecule (Fig. 6c). Effects
of mutations in catalytic residues in terms of afﬁnity changes of cGMPTable 1
List of experimentally known mutations for Cancer in PDE6A Gene encoding Gaf-A and
Catalytic Domain of PDE6α chain (predicted ΔΔG in kcal/mol).
Mutations Gene mCSM SDM2 DUET mCSM-PPI mCSM-NA
PDE6A Gaf-A
F162 L PDE6A −1.381 −1.95 −1.492 −1.027 −0.549
V141 M PDE6A −0.951 −0.98 −0.61 −1.576 −4.978
R93L PDE6A −1.211 −1.01 −1.297 −1.358 −2.222
PDE6A catalytic domain
D600N PDE6A −1.011 −0.934 −1.554 −1.287 −3.088
F742 L PDE6A −1.751 −0.872 −0.706 −1.512 −1.702
F776 L PDE6A −1.504 −0.72 −0.706 −1.281 −1.702molecules with catalytic domain are predicted through mCSM-NA and
are mapped on catalytic pocket of PDE6α (Fig. 6a & b). Sidechain
atoms of His-563, His-559 formed a network of ionic bonds with Zn2+
ion. Interactions of Mg2+ and Zn+2 ions with cGMP molecule can also
be seen in Fig. 6c. Ring-to-edge interactions of Asp-720 and π-π stacking
interaction of Phe-776 may contribute to the orientation of cGMP mol-
ecule in the catalytic pocket. Other important catalytic residues i.e. Tyr-
558, Asp-600, Thr-669, Leu-671, Glu-741, Phe-742, Met-760, Gln-773
were observed to have proximal interactions with the cGMP molecule.
All the residues given in Fig. 6b are conserved catalytic residues of the
phosphodiesterase family [6,65]. mCSM-NA analysis of saturated muta-
tions in the catalytic pocket revealed highly destabilizing effects for
three mutations which are discussed below. These mutations are also
reported in the COSMIC database. Of these three highly destabilizing
mutations, one is D600N which is reported to be a missense mutation
in the catalytic pocket of PDE6α and PDE6β in retinitis pigmentosa as
well as in the COSMIC database.
D600N: In the catalytic pocket of PDE6α and PDE6β, Asp-600 is
highly conserved residue that binds to Mg2+ and Zn2+, ion which in
turns interacts cGMP molecule. In the surrounding residue environ-
ment, Asp-600 forms van der Waals interactions with His-603 and
sidechain atoms of His-559 and Tyr-553 form proximal hydrophobic
bonds with Asp-600. Backbone atoms of Asp-600 are also making
carbon-π interaction with the His-631 and His-599 as depicted in
Fig. 7a. Four histidine residues, i.e. His-559, His-599, His-603, His-631,
Fig. 5. a) illustrates interactions between Arg-93 (R93 in cyan color) with the cGMP molecule (white) as well as with the neighboring residues (green color) of the wild-type PDE6αβ.
Hydrogen bonds (red dotted lines), proximal hydrophobic interactions (small grey dotted lines), ionic interactions (yellow dashed lines) and carbon-π interactions (white dotted
lines). b) Depicts carbon-π interaction (grey dotted line) between mutant Leu-93(labelled in red color) and Tyr-172 while loss of interactions with neighboring environment
residues and cGMP molecule can also be observed. c) Depicts interactions of Val-141(cyan) with cGMP molecule (white) and neighboring residues (green) in the environment of
the wild-type PDE6αβ complex. Hydrogen bonds and van der wal interactions are shown by red lines; hydrophobic interactions (small grey dotted lines) and carbon-π
interactions of Val-141 with the ring atoms of Phe-97 and Phe-113 are shown in dark grey dotted lines. d) Represents mutant Met-141 (labelled in red) binding with nearby
residues (green) of the environment through various non-covalent interactions; hydrogen bonds (red dotted lines), hydrophobic interactions (light grey dotted lines) and
methionine-π interaction (dark grey dotted lines) with ring atoms of Phe-97. Loss of interaction between cGMP molecule and mutant V141 M is also shown. e) Illustrates non-
covalent interactions of wild type F162 (labelled in blue with cGMP (white) and nearby residues (green). Hydrogen bonds are shown in red dotted lines, proximal hydrophobic
interaction in small grey dotted lines while inter-residue donor-π interactions are highlighted in dark grey dotted lines. f) represents binding of F162 L mutant (labelled in red)
with its three nearby residues (leu-89, Asp-159, Thr-156) through weak hydrogen bonds (red dotted lines) and hydrophobic interactions (small grey dotted lines). Loss of binding
with cGMP molecule is also evident mutant complexes (b,d,f).
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PDE6. Missense mutation D600N in PDE6α as well as in PDE6β has
been reported both for cancer and retinitis pigmentosa of photoreceptor
cells. Analysis of D600N using mCSM-PS, SDM, DUET and mCSM-PPI
predicts it as a mildly destabilizing mutation (see Table 1). However,
mCSM-NA predicted it as a highly destabilizing mutation (ΔΔG value
b−2.00 kcal/mol) (Table 1). Intermezzo analysis showed D600N exhib-
ited loss of ionic bonding betweenMg2+ andmutant residues.With the
residues in the surrounding environment, D600Nmutant shows donor-
π interactionwith His-559 andHis-631while loses its native hydropho-
bic interaction with other two histidine residues. In D600N, side chain
atomsof Tyr-553 formhydrogen bondwith Asn-600 as shown in Fig. 7b.
F742L: Ring atoms of F742 forms one edge-to-edge and one atom-
ring interaction with the cGMP molecule. While with the neighboring
residues, backbone atoms of F742 forms van der Waals interaction
with the backbone and sidechain atoms of Val-738 and Ala-739. Addi-
tionally, side chains of Val-738, Gln-745 and Met-761 interact with
Phe-742 through hydrophobic interactions. In addition to this, side
chain atoms of Met-760 make methionine-π and carbon-π interaction
with the ring atoms of Phe-742 as shown in Fig. 7c. Mutation analysis
of F742 L showed it a mildly destabilizing mutation when analyzed
through mCSM, SDM, DUET, mCSM-PPI and mCSM-NA as all of them
predicted ΔΔG score b 0 (see Table 1). Intermezzo analysis of F742L re-
vealed loss of hydrophobic interaction between ring atoms of F742 and
cGMP. Backbone atoms of Leu-742 form a dense network of hydropho-
bic interactionswith the sidechains of surrounding residues i.e. Val-738,
Glu-741, Met-760, Met761 and Gln-745 as shown in Fig. 7d.F776L: In wild type PDE6α, ring atoms of Phe-776 is forming
ring-ring interaction with the purine ring of cGMP. In addition to
this, sidechain atom of the Phe-776 is also making a hydrogen
bond with the edge of cGMP ring structure. Further, carbon-π in-
teraction is observed between the sidechain atoms of cGMP mole-
cule and Val-780 and Gln-773 is interacting with the backbone
atom of F776 through two hydrogen bonds as shown in Fig.
7e. Missense mutation F776L show mild destabilizing effect
(Table 1) as predicted by mCSM, SDM, DUET, mCSM-PPI and
mCSM-NA analysis. Intermezzo analysis of F776L exhibited loss
of ring - ring and hydrogen bonding with cGMP molecule. With
the surrounding environment Leu-776 interacts with Leu-772,
Gln-773 and Cys-781 through hydrogen bonds while backbone
atoms of Leu-776 form carbonyl interaction with the sidechain
atoms of Ile-777 and Gln-773 (shown in Fig. 7f).
3.3. Mutation Affecting PDE6αβ Dimer Interface
The heterodimeric interface of PDE6 αβ complex is stabilized
by two long juxtaposed α-helices, which acts as a backbone in
the structure. The central helices were built based on experimen-
tally known template structure of PDE2. To understand the impact
of mutations on the subunit interfaces, we carried out computa-
tional saturation mutagenesis of interface residues. mCSM-PPI
analysis revealed 94% mutations as mildly destabilizing while
26% were predicted as highly destabilizing mutations in interfacial
residues of the PDE6α chain. Whereas approximately 97%
Fig. 6. a) Heat map based on mCSM-NA predicted ΔΔG values showing the average stability changes upon mutation in cGMP binding residues of PDE6α catalytic domain. (b). Zoom in
view illustrating the average effect of mutations in critical catalytic residues that binds cGMP molecule. Colored gradient scale shows the mutation effects; stabilizing (N0.00 kcal/mol)
(blue), slightly destabilizing (≥−2.0 kcal/mol) (white) and highly destabilizing (b−2.00 kcal/mol) (highlighted in red) c) Intermezzo analysis depicts interatomic interactions between
cGMP molecules and wild type residues of catalytic domain of PDE6 through non-covalent interactions. Red dotted lines indicate ionic bonds between His-563, His-559 and Zn2+ ion.
Metal interactions involving Zn2+ ion and cGMP molecule are shown in blue color. Weak hydrogen bonds are shown in small red dotted lines. π-π stacking interaction and aromatic
interaction of Phe-776 with the cGMP molecule within the catalytic pocket are shown in white and cyan colored dotted lines respectively. Other important catalytic residues i.e. Tyr-
558, Asp-600, Thr-669, Leu-671, Glu-741, Phe-742, Met-760, Gln-773 are shown to have undeﬁned interaction with the cGMP molecule depicted in grey small dotted lines.
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tations are highly destabilizing mutations in the PDE6β chain as
shown in Supplementary Fig. 4a. The predicted effects of the mu-
tations were mapped onto the central helical regions of PDE6αβ
dimer (Supplementary Fig. 4b and c). The regions shown in red
color represent the dimer interface residues, which upon mutation
might disrupt the intertwined helical organization and ultimately
result in loss of PDE6αβ structural stability.
At the heterodimeric interface of the PDE6αβ complex two residues
(Phe-249 and Phe-426) were observed to form a network of hydropho-
bic, inter-residue, ring-ring and atom-ring interactions with Phe-424.
Mutations in these residues are discussed below in detail.
F249G: In PDE6α chain, ring atoms of Phe-249 forms ring-to-edge
interactions with the Phe-424 in PDE6β chain. Helices of PDE6α and β
chains are also stabilized by the hydrophobic interaction between the
sidechain ring atoms of Phe-249 and Trp-427 respectively. In the sur-
rounding environment Phe-249 forms inter residue atom-ring interac-
tion with Ser-244 and Ser-246 (Fig. 8a) which might help in the
spatial orientation of Phe-249 as an interfacial residue. The F249Gmuta-
tionwas predicted asmildly destabilizingmutation bymCSM- PPI (ΔΔG
=−1.288 kcal/mol) (Table 2), which results in the loss of dimeric inter-
face interaction between PDE6β chain residues (Phe-424 and Trp-427)
(see Fig. 8b).F424N: In PDE6β chain, Phe-424 stabilizes the heterodimer
complex through a mesh of hydrophobic and aromatic interactions
involving the ring atoms of Phe-424(PDE6β) and Phe-249
(PDE6α). In the environment, Phe-424 makes ring-ring (π-π)
stacking interaction with ring atoms of Trp-427, it is also stabilized
by the ring -edge inter-residue interaction with Leu-421 (see
Fig. 8c). F424N was predicted as a mildly destabilizing mutation
with mCSM-PPI predicted ΔΔG of −1.591 kcal/mol as shown in
Table 2. Intermezzo analysis indicated a loss of inter-chain interac-
tion with Phe-249 (PDE6α), Asn-424 shows van der Waals interac-
tions with Leu-421. It also has inter-residue ring and pi-group
interaction with Ser-420 (see Fig. 8d).
F426A: At the dimeric interface, F426 in the PDE6α chain forms a
ring-edge hydrophobic interactionwith Leu-240 and it alsomakes a hy-
drogen bondwith the Asn-244 of PDE6β chain, and an inter-residue in-
teraction with the backbone atoms of Leu-240 and Asn-244. In the
PDE6α chain it interacts with surrounding residues (Ser-430 and Leu-
423), as shown in Fig. 8e. The F426Amutation is predicted to highly de-
stabilize the dimeric interface interaction (ΔΔG=−2.548 kcal/mol), in
which the alanine substitution results in the loss of interactions with
Leu-240 and Asn-44 of the PDE6β chain. Ala-426 forms interactions
with the sidechain atoms of neighboring residues (Leu-423 and
Ser-430) as shown in Fig. 8f.
Fig. 7. Interatomic interaction analysis of wild-type and mutant PDE6 catalytic residues a) depicts Asp-600 (cyan colored) bound to cGMP (white), Mg2+ (green sphere) and nearby
residues (green) within the catalytic pocket. Ionic interactions (blue), hydrogen bonds and van der Waals (red color), hydrophobic interaction (grey small dotted lines) and carbon-π
interactions (dark grey dotted lines). b) Illustrates interaction network of missense mutation Asn-600 (labelled in red) with cGMP (white), Mg2+ (green sphere) and surrounding
catalytic residues (green). Hydrogen bonds are shown in red dotted lines whereas donor-π interaction with wheat colored dotted lines. c) Shows dense network of hydrophobic and
ring interactions between Phe-742 (cyan), cGMP (white) and surrounding catalytic pocket's residues (green). Hydrogen bonds are depicted in red dotted lines, atom-ring interactions
including methionine -π interactions and carbon-π interactions are shown in dark grey dotted lines. Proximal hydrophobic interactions (small grey-dotted lines) and undeﬁned
interactions are shown as dense network of small dots. d) Illustrates dense proximal hydrophobic interaction network (small grey dotted lines) of missense mutation F742 L (Leu-742
labelled with red) with neighboring residues (green). Loss of interaction between cGMP (white) and Leu-742 is also depicted in graphical depiction. e) graphical illustration of
Intermezzo analysis of F776 (cyan) with cGMP (white) and nearby surrounding residues (green) of catalytic domain of PDE6. Hydrogen bonds are shown in red dotted lines,
hydrophobic interactions are shown in small dotted lines, ring-ring interactions between F776 and cGMP are shown in grey dotted lines while carbon-π interactions of F776 with
neighboring residues are shown in wheat color. f) Illustrating hydrogen bond (red dotted lines) and carbonyl interaction (magenta color) of missense mutation Leu-776 (F776 L
labelled in red) with neighboring residues (green). Loss of binding between F776 L and cGMP was also observed in intermezzo analysis.
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cGMP-speciﬁc phosphodiesterases regulate a myriad of cellular sig-
naling processes through critical regulation of the cGMP messenger
molecule and any disruption/dysregulation in the signaling pathways
may lead to downstream pathophysiological impacts [2].
Evidence of association of PDE6 with cancer progression and vision
loss, will be strengthened if we are able to estimate the structural and
thermodynamics effects ofmutations in cGMP signaling proteins. To de-
cipher the impacts of mutations on protein stability, structural informa-
tion of PDE6 is necessary to piece together the molecular details of its
activation and deactivation. Although crystal structures of individual
domains of different isoforms of PDE6 have been determined and a to-
pological architecture depicting PDE6 domain's assembly is available
at a very low resolution, a completemultimeric structure is not available
for PDE6 for rod cells in human retina [29,57]. It is challenging to obtain
an adequate puriﬁed form of PDE6 protein in an active form via recom-
binant (eukaryotic/prokaryotic) expression systems to solve the
multimeric assembly of the structure [15]. To predict the structure of
multiprotein assembles is a challenging task for structural bioinformat-
ics. In a protein family, residues present within a domain share a strong
interaction network of almost conserved residues but when multiple
domain are involved, it becomes difﬁcult to predict their spatial assem-
bly as a fewer residues are involved in domain-domain interaction and
conservation among these residues is not extensive. In the PDE6 hetero-
dimer structure, a divide and conquer rule was followed in which indi-
vidual domains were modelled by taking the advantage of the highsequence identity with their homologous. Individual domain models
with high prediction accuracy were then assembled on the long
interconnecting helices (substructures) borrowed from the crystal
structure of PDE2 which shares less similarity with the PDE6 at the do-
main level. Thus, PDE6 domains were built using PDE5 and PDE6C do-
mains and information of juxtaposed helices and domain assembly
was inferred from the solved structure of PDE2. Unlike PDE2, PDE6αβ
is a heterodimer, which has about 70% in sequence identity between
the chains while the structure is in open conformation with cGMP
bound within the conserved cGMP binding and catalytic pockets. In
the past few years, sequencing of the cancer genome has yielded a
rich amount of mutation data for PDE6 α and β chains. To deﬁne the
mechanistic impacts of PDE6 mutations in cancer, we have described
here an insilicoworkﬂow for the analysis of relative changes in protein
structure and stability due to missense mutations. We have discussed
the effects of mutation with respect to change in protein stability and
its interaction pattern with the cGMPmolecule and its surrounding res-
idue environment in order to unravel the link between the mutation
and disease phenotype. We identiﬁed mutations that are highly
destabilizing with respect to cGMP binding and/or metal ion binding
and in addition, have disruptive impact on the dimeric interface.
We also observed thatmissensemutations in PDE6 that are reported
in COSMIC for cancer are also reported for retinitis pigmentosa in vari-
ous experimental studies [28,33]. Earlier it was believed the PDE6 is
only expressed in photoreceptor cells but now it is evident from various
studies that retina -speciﬁc PDE6 is also expressed in the perinuclear re-
gion of endothelial cells and has a signiﬁcant role in compartmentalized
Fig. 8. a)Graphical description ofwild type Phe-249 (cyan)present at thedimeric interface of PDE6A chain that is found to establish interactionwith interfacial residues of PDE6B (Phe-424
and Trp-427). Hydrogen bonds are shown in red dotted lines, hydrophobic interactions are highlighted in grey dotted lines. Ring-ring (π-π stacking) interactions are highlighted in black
while inter residue interactions are shown in orange color. b) showsmutant Gly-249 (labelled with red) present at the dimeric interface of PDE6A, which establishes hydrogen bond (red
dotted lines) and carbonyl interactions (magenta dotted lines)with neighboring residues that are presentwithin its chainwhile disrupting strong interactions at protein-protein interface
residues as predicted bymCSM-PPI c) shows residue Phe-424 (cyan) performing a dense network of hydrophobic (grey dotted lines), ring-ring (black dotted lines), atom-ring interactions
(magenta dotted lines) and inter residue interactions (orange) with neighboring residues of its PDE6A chain as well aswith interfacial residues of PDE6B chain. d)Mutation to Asparagine
(Asn-424) in PDE6B is predicted to be highly destabilizing, disrupting dimer interaction with Phe-249 present at PDE6A as predicted by mCSM-PPI. While Asn-424 retains carbonyl
interactions (magenta dotted lines), hydrogen bonds and van der wal interactions (red dotted lines) and inter-residue interactions (orange) with neighboring residues that are
present within its chain. e) represents PDE6A chain residue Phe-426, present at dimer interface performing atom-ring interactions (grey dotted lines) and inter residue interactions
(orange) with interfacial residues of PDE6B while it also establishes hydrogen bonds (red dotted lines) with other residues of same chain. f) Mutation to Ala-426 in PDE6A is forming
carbonyl (magenta) and hydrogen bonds (red dotted lines) with the nearby residues of its chain while losing afﬁnity with PDE6B interfacial residues as predicted by mCSM-PPI.
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zymes in breast cancer cell lines [18] suggest that in cancer the negative
regulatory mechanism of PDE6, which maintains the concentration of
cGMP, is no longer active and this affects the downstream subcellular
signaling pathways [14].
The high frequency of PDE6 mutations in skin cancer suggest a pos-
sible crosstalk of cGMP signaling pathway and mitogen-activated
protein kinase/extracellular signal-regulated kinase (MAPK/ERK) sig-
naling pathway responsible for approximately 40% of human melano-
mas. Cross talk of components of the cGMP signaling pathway and
Ca2+ signaling attenuates MAPK/ERK proliferative signaling in mela-
noma cells suggest that any change/mutation and disruption in cGMP
signaling proteins will be negatively affecting MAPK/ERK proliferative
signaling in melanoma cells [51].
Deciphering the speciﬁc role of mutations as etiological factors
for various diseases relies on their ability to induce structural alterations
in proteins to an extent that they inﬂuence pathophysiological
outcomes. Unlike infectious diseases where genomic mutations inTable 2
Effect Of Mutations on Dimerization of PDE6αβ Complex Predicted Through mCSM-PPI
(predicted ΔΔG in kcal/mol).
Mutation GENE mCSM-PPI
F426A PDE6A −2.548
F249G PDE6A −1.288
F424 N PDE6B −1.591pathogens are most likely attributed to either resistant or virulent
strains, mutations in human genes that drive various cancers and inﬂu-
ence different cell signaling mechanisms, needs comprehensive under-
standing at the subcellular and structural levels. The current study is
primarily focused on understanding the structural organization of the
PDE6αβ complex and the impact of mutations on cGMP binding, cata-
lytic activity and heterodimer assembly. The objective of this study
was to understand the possible structural effects of experimentally-
knownmissensemutations on the recognition of the activatormolecule
(cGMP) within the allosteric and catalytic binding pockets. We also
evaluated and discussed the structural variations and change in binding
afﬁnity of the PDE6 dimer, because missense mutations at the dimer
interface residues may affect structure and function of PDE6. In the
absence of an experimentally solved structure for the full chain of a
multidomain protein like PDE6, it is extremely challenging to model a
plausible conformerwith accurate orientation of the domains. Although
the template identities are low and speciﬁc to individual domains, we
were able to model the full chain heterodimeric complex of PDE6
and reasonably retain the multi-domain architecture of eukaryotic
phosphodiesterases.
In conclusion, we modelled the structure of human PDE6αβ com-
plex and used a set of state-of-the-art computational tools to under-
stand the effects of mutations on thermodynamic stability, stability of
the dimer interface, interactionswith cGMP and catalytic activity. Struc-
tural changes due to mutations that alter binding patterns of cGMP in
catalytic and Gaf-A domain were analyzed using experimentally
known and a computationally saturated set of mutations. Further, the
388 A. Maryam et al. / Computational and Structural Biotechnology Journal 17 (2019) 378–389saturation mutagenesis of residues in the heterodimeric interface was
also analyzed to provide prospective information about the possible ef-
fects of mutations if they occur at the dimer's interfaces. While most of
the observations are computationally simulated, they provide a basis for
prioritization of future experimental approaches to establish the struc-
tural link between mutations in PDE6 and phenotypic outcomes like
cancer and retinitis pigmentosa.
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